Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 29;5(1):93.
doi: 10.1186/s43058-024-00631-7.

Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system

Afiba Manza-A Agovi  1 , Caitlin T Thompson  2 , Kevin J Craten  2 , Esther Fasanmi  3 , Meng Pan  4 , Rohit P Ojha  2 , Erika L Thompson  5
Affiliations

Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system

Afiba Manza-A Agovi et al. Implement Sci Commun. .

Abstract

Background: Long-acting injectable cabotegravir plus rilpivirine (LAI CAB/RPV) has several potential benefits over daily oral formulations for HIV treatment, including the potential to facilitate long-term adherence and reduce pill fatigue. We aimed to assess facilitators of and barriers to LAI CAB/RPV implementation and delivery through the perspectives of physicians and clinical staff, and the experiences of LAI CAB/RPV use among people living with HIV (PLWH) at a Ryan-White supported safety-net clinic in North Texas.

Methods: We conducted semi-structured interviews with recruited clinic staff (physicians, nurses, and support staff) involved with LAI CAB/RPV implementation and PLWH who switched to LAI CAB/RPV and consented to participate in individual interviews. Data were collected from July to October 2023. Our interview guide was informed by the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM), and Proctor Implementation Outcomes frameworks. Qualitative data were analyzed using a rapid qualitative analysis approach to summarize key themes.

Results: We recruited and interviewed 15 PLWH who transitioned to LAI CAB/RPV and 11 clinic staff serving these patients. PLWH conveyed that emotional and informational support from family or a trusted clinician influenced their decision to switch to LAI CAB/RPV. PLWH also reported that injectable treatment was more effective, convenient, and acceptable than oral antiretroviral therapy. Clinic staff and physicians reported that staff training, pharmacist-led medication switches, flexible appointments, refrigeration space and designated room for injection delivery facilitated implementation. Clinic staff cited medication costs, understaffing, insurance prior authorization requirements, and lack of medication access through state drug assistance programs as critical barriers.

Conclusions: Our study offers insights into real-world experiences with LAI usage from the patient perspective and identifies potential strategies to promote LAI CAB/RPV uptake. The barriers to and facilitators of LAI CAB/RPV program implementation reported by clinic staff in our study may be useful for informing strategies to optimize LAI CAB/RPV programs.

Keywords: HIV/AIDS; Implementation science; Injectable cabotegravir/Rilpivirine; Long-acting injectable antiretroviral therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

See all similar articles

References

    1. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112–23. 10.1056/NEJMoa1904398 - DOI - PubMed
    1. Food and Drug Adminstration (FDA). FDA approves cabenuva and vocabria for the treatment of HIV-1 infection January 27, 2021. 2022. Available from: https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-....
    1. Cabotegravir and rilpivirine drug information. 2022. Available from: https://clinicalinfo.hiv.gov/en/drugs/cabotegravir-rilpivirine/patient. Cited 11/18/2022.
    1. Cabenuva [package insert]. Silver Spring, MD: U.S. Food and Drug Administration; 2022. cited 2024 Aug 22. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006....
    1. ViiV Healthcare. ViiV Healthcare announces FDA approval of Cabenuva for use every two months [Internet]. 2022 Jan 31. cited 2023 Feb 2. Available from: https://viivhealthcare.com/hiv-news-and-media/news/pressreleases/2022/ja....

LinkOut - more resources